Breaking News
April 20, 2018 - Teva and Procter & Gamble Company terminate PGT Healthcare partnership
April 20, 2018 - People diagnosed with traumatic brain injury may have increased risk of Parkinson’s disease, shows study
April 20, 2018 - Researchers use smartphone to diagnose people infected with Loa loa worm
April 20, 2018 - College students with autism have high rate of suicidal thoughts
April 20, 2018 - Study sheds light on how the HSC niche is maintained
April 20, 2018 - Drug test spurs frank talk between hypertension patients and doctors
April 19, 2018 - Low-cost deworming drug improves female farmers’ physical fitness
April 19, 2018 - Genome editing identifies neural circuit behind leptin’s anti-obesity and anti-diabetes effects
April 19, 2018 - Many European countries lack comprehensive policy to eliminate viral hepatitis
April 19, 2018 - Young people with ADHD ‘more likely’ to come from deprived neighbourhoods
April 19, 2018 - SLU professor discovers new biomarkers for chlorine gas exposure
April 19, 2018 - Study proposes new mechanism that may contribute to gender differences in weight control
April 19, 2018 - Sleep restriction therapy does not interfere with insomnia patient’s driving ability, research shows
April 19, 2018 - Deep brain stimulation offers relief to UTHealth patient with treatment-resistant depression
April 19, 2018 - Study shows fatty fish and camelina oil boost HDL and IDL cholesterol
April 19, 2018 - FDA Alert: Euphoric Capsules by Epic Products: Recall
April 19, 2018 - Researchers identify peptide produced during cartilage deterioration as a potential source of osteoarthritis pain
April 19, 2018 - New breakthrough may allow scientists to orchestrate tissue regeneration in humans
April 19, 2018 - SYGNIS AG introduces new TruePrime apoptotic cell free DNA amplification kit
April 19, 2018 - Innovative device shows promise in capturing and releasing circulating tumor cells
April 19, 2018 - Researchers shed light on role of striosomal neurons in reinforcement learning
April 19, 2018 - Genetic make-up impacts long-term effectiveness of phobia treatment
April 19, 2018 - Novel biomarker can distinguish malignant lung nodules
April 19, 2018 - Study reports promising novel approach to treat therapy resistant pediatric brain tumors
April 19, 2018 - One-Hour Plasma Glucose Useful Predictor of Diabetic Retinopathy
April 19, 2018 - Hydroxychloroquine no more effective than placebo for relieving osteoarthritis hand pain
April 19, 2018 - Transplanted livers have a protective effect and reduce potential for organ rejection
April 19, 2018 - Researchers develop new method to study activity of inflammatory cells
April 19, 2018 - Researchers discover highly antibiotic resistant superbugs in Gulf States
April 19, 2018 - Interaction between dioxin and HLA gene variant activates events associated with rheumatoid arthritis
April 19, 2018 - Eyes of adolescents could be associated with increased risk of cardiovascular disease in later life
April 19, 2018 - U.S. Women Less Likely Than Men to Get Statins After Heart Attack
April 19, 2018 - Health Canada grants cannabis cultivation license to High Park Farms
April 19, 2018 - Atypical brain development observed in preschoolers with ADHD symptoms
April 19, 2018 - SC Johnson releases annual Sustainability Report
April 19, 2018 - Positive attitudes about aging reduce risk of dementia in older adults
April 19, 2018 - Environmental pollutants found to worsen rheumatoid arthritis
April 19, 2018 - UT Southwestern scientists discover protein linked to metastatic breast cancer
April 19, 2018 - Study highlights need for further evidence to improve symptom management in end of life care
April 19, 2018 - Detecting diminished dopamine-firing cells inside brain could reveal earliest signs of Alzheimer’s
April 19, 2018 - Uniqsis offers high-power LED light unit for scalable flow photochemistry reactions
April 19, 2018 - Case study shows how intravascular ultrasound imaging helps detect acute aortic syndrome
April 19, 2018 - Research reveals new mechanism by which HIV evades the immune system
April 19, 2018 - Nanodisc-delivered cancer treatment helps eliminate tumors
April 19, 2018 - Functional connectivity MRI could help detect brain disorders and diseases
April 19, 2018 - Finding better way to quantify neuropathy symptoms and treatment efficacy
April 19, 2018 - Study examines effectiveness of caregiver education about sickle cell trait
April 19, 2018 - High-resolution images of tumor vasculature using new technology
April 19, 2018 - Lack of sleep may be linked to risk factor for Alzheimer’s disease
April 19, 2018 - Study finds neurotransmitter may play a role in alcohol relapse, addiction
April 19, 2018 - Researchers build molecular networks of calcific aortic valve disease
April 19, 2018 - Researchers develop highly specific apoptosis assay for pharmacodynamic analyses of tumor specimens
April 19, 2018 - Scientists decipher mechanism of chemotherapy induced female infertility
April 19, 2018 - New insight may allow researchers to design drugs that improve immune responses to vaccines
April 19, 2018 - FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia
April 19, 2018 - Researchers uncover origin of virus-fighting plasma B cells
April 19, 2018 - Study finds no evidence of lower intelligence in young children who had anesthesia
April 19, 2018 - Baboons break out of research facility briefly
April 19, 2018 - Study shows how deployment time increases risk of suicide attempt in soldiers
April 19, 2018 - Specific odors from malaria infected individuals attract more mosquitoes
April 19, 2018 - FDA Alert: Rhino 69 Extreme 50000 by AMA Wholesale: Recall
April 19, 2018 - Top HIV cure research team refutes major recent results on how to identify HIV persistence
April 19, 2018 - Experts propose new solutions to increase benefit, affordability of targeted cancer medicines
April 19, 2018 - Deficiency of innate immune adaptor TRIF shortens survival time of ALS mice
April 19, 2018 - New machine learning method offers better way to detect heart disease
April 19, 2018 - CNIO researchers determine structure of protein complex related to cell survival
April 19, 2018 - Faith-based diabetes support program launched by UTSA research team
April 19, 2018 - Volumetric Laser Endomicroscopy Helps ID Barrett’s Regions
April 19, 2018 - Engineered cartilage template to heal broken bones
April 19, 2018 - New computational framework accurately predicts drug-drug and drug-food interactions
April 18, 2018 - Some human cancers may be result of evolutionary accidents, research finds
April 18, 2018 - Higher levels of education linked to lower dementia risk in older African Americans
April 18, 2018 - Smoking Puts Blacks at Higher Risk for Heart Failure
April 18, 2018 - Physiotherapist contributes to guidelines for knee cartilage treatment
April 18, 2018 - Researchers use ‘top-down proteomics’ strategy to get new insights into cancer
April 18, 2018 - Physician assistants less likely to accurately diagnose early stage skin cancers
April 18, 2018 - New faster, streamlined method for bowel cancer detection and treatment
April 18, 2018 - Researchers identify new Listeria species in Costa Rica
April 18, 2018 - Novel interactive diagram shows many facets of mild traumatic brain injury
April 18, 2018 - Short sleep linked to obesity in children and adolescents
Study of men with inherited DNA repair mutations opens new therapeutic avenues in prostate cancer

Study of men with inherited DNA repair mutations opens new therapeutic avenues in prostate cancer

image_pdfDownload PDFimage_print

Selected by the American Society of Clinical Oncology (ASCO) to first outing during its Genitourinary Cancers Symposium, Translating Evidence to Multidisciplinary Care, February 8 – 10 (San Francisco, USA), Joaquin Mateo, Principal Investigator of VHIO’s recently created Prostate Cancer Translational Research Group, will today reveal findings from a retrospective and international study showing for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients.

Timed to coincide with Joaquin Mateo’s presentation at this week’s ASCO meeting, these results will be published today in the prestigious journal European Urology.

Given that standard therapies traditionally target the hormonal basis of prostate cancer – as opposed to genetic mutation – the team sought to evidence whether patients with metastatic prostate cancer with identified DNA-repair gene mutations, typically found in one out of every ten of these patients, could derive similar benefit from treatment with standard of care therapies. In so doing, they aimed to establish the prognostic and predictive value of these alterations towards a more personalized stratification of patients.

Between 2005 – 2015, the most common cancer for men was prostate cancer with an estimated 1.6 million cases. Recent findings suggest that while it is relatively rare for prostate cancer to spread in the body, metastatic and aggressive prostate cancer is on the rise.

“While prostate tumors are more generally slow-growing than other cancers, the reality in Spain alone is that this disease claims the lives of 6,000 individuals every year. Translational studies aimed at better identifying which patients would most likely benefit from both standard therapies as well as novel anti-cancer approaches are critical if we are to ultimately improve outcomes for patients with metastatic disease”, observes Joaquin, first author of the study.

Until quite recently, prostate cancer was considered to be exclusively dependent on male androgens fuelling prostate cancer cell growth, and the majority of anti-cancer therapies have thus focused on tackling this tumor type from this angle. Current research is rapidly transforming the way in which prostate cancer is both considered and managed, paving the way for more effective and tailored treatment approaches.

Previous findings published in Cell in 2015 showed that between 20-25% of patients with metastatic prostate cancer had DNA-repair related mutations as well as BRCA mutations, or similar.

In 2016, Mateo and colleagues evidenced that DNA-repair gene mutations are found inherited in one out of every ten men with metastatic prostate cancer. This discovery, published in The New England Journal of Medicine, has since placed these mutations firmly under the lens in efforts aimed at benefiting an increasing number of these patients.

Additional research has therefore centered on showing whether individuals with these identified mutations could better respond to other treatments. Clinical findings also reported by Joaquin and co-collaborators from the Institute of Cancer Research – Royal Marsden NHS Foundation Trust (London, UK), revealed that some of these patients responded to PARP inhibitors, which are already approved in the case of metastatic breast cancer and ovarian cancer in carriers of mutations in BRCA.

This discovery has since led to several currently ongoing international clinical trials in prostate cancer. The next step was to analyze treatment response in these patients to establish whether this inherited genetic variation affects the efficacy of therapy.

In this latest study, results were analyzed for a total of 390 metastatic prostate cancer patients with DNA-repair gene mutations to assess response to standard treatments. Findings indicate that patients with BRCA mutations respond to these therapies in a similar way to other patients with metastatic prostate cancer patients without these mutations.

Overall survival and disease-free progression were therefore comparable and no significant differences in response rate to first-line treatment were observed. In addition, a trend toward greater overall survival was noted in those patients with mutations who had participated in studies with PARP inhibitors or platinum-based therapy.

“Since this cohort of patients is the first with long-term data available on the response to post-therapy with PARP inhibitors and platinum-based agents, our research also marks an important first. We are seeing that patients with these mutations not only benefit from standard treatments, but may also have additional therapeutic options available”, explains Joaquin.

“While our data are still preliminary, I believe that we have every reason to be optimistic about these initial results. Importantly, with several trials with PARP Inhibitors for prostate cancer currently underway at VHIO, new clinical data to emerge from these studies will hopefully further support the use of these inhibitors in the treatment of our patients”, he concludes.

Joining forces with VHIO’s Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group Cancer led by Joan Carles, also located within the Vall d´Hebron Barcelona Hospital Campus, Joaquin’s Prostate Cancer Translational Research Group will pioneer research aimed at translating prostate cancer genotypes into phenotypes and a clinically-relevant classification of the disease. These teams will also seek to build a precision medicine core for prostate cancer patients.

His group’s expertise, combined with that of Joan Carles, will accelerate the translation of the use of PARP inhibitors as a more effective therapy for metastatic prostate cancer patients to the clinic. Currently open clinical studies performed at VHIO, matched to the molecular alterations and specificities detected in individual patients, are possible thanks to its renowned prescreening program, pioneered by VHIO’s Cancer Genomics and Molecular Oncology Groups, led by Ana Vivancos and Paolo Nuciforo, respectively.​

Source:

Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

Tagged with:

About author

Related Articles